Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.61 |
| ▸ | EGFR | P00533 | 9/20 | 0.58 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.54 |
| ▸ | INSR | P06213 | 2/20 | 0.53 |
| ▸ | IGF1R | P08069 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | ROS1 | P08922 | 1/20 | 0.53 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24940066 | 1.00 | ALK (0.61) | ALKEGFRMAP4K1INSRIGF1R | |
| SCHEMBL30105829 | 0.94 | ALK (0.62) | ALKEGFRMAP4K1INSRIGF1R | |
| SCHEMBL30105855 | 0.90 | ALK (0.60) | ALKEGFRMAP4K1INSRIGF1R | |
| SCHEMBL24940068 | 0.90 | ALK (0.60) | ALKEGFRMAP4K1INSRIGF1R | |
| SCHEMBL30105875 | 0.89 | EGFR (0.62) | ALKEGFRMAP4K1INSRIGF1R | |
| SCHEMBL24940082 | 0.89 | EGFR (0.62) | ALKEGFRMAP4K1INSRIGF1R | |
| SCHEMBL24940742 | 0.88 | ALK (0.66) | ALKEGFRMAP4K1INSRIGF1R | |
| SCHEMBL30105786 | 0.88 | ALK (0.66) | ALKEGFRMAP4K1INSRIGF1R | |
| SCHEMBL30105843 | 0.88 | EGFR (0.58) | ALKEGFRMAP4K1 | |
| SCHEMBL24940885 | 0.88 | EGFR (0.62) | ALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| WO-2023006088-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION AND USE THEREOF | 浙江大学智能创新药物研究院 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | ALK 68/4885EGFR 1/4885MAP4K1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.